Literature DB >> 8670166

C-myc is required for the G0/G1-S transition of primary hepatocytes stimulated with a deleted form of hepatocyte growth factor.

G G Skouteris1, C H Schröder.   

Abstract

Primary rat hepatocytes stimulated in vitro with the addition of a deleted form of hepatocyte growth factor (dHGF) enter the S-phase 48 h after addition of the growth factor. The c-myc gene is believed to play a role in a variety of cellular stages, such as proliferation, differentiation and cell death. In primary hepatocytes c-myc was expressed constitutively at both mRNA and protein levels, independently of the growth conditions. dHGF induced significant c-myc expression at times correlated with the long-lasting pre-S phase, and no induction was observed at the G0/G1 traverse compared with the unstimulated hepatocytes. An antisense construct coding for all three exons of c-myc was imported into hepatocytes by using the transferrin receptor-mediated endocytosis methodology (transferrinfection). Expression of the antisense construct inhibited the biosynthesis of the c-Myc protein, however it did not interfere with the expression of c-met, encoding the receptor for HGF/dHGF. Continuous expression of the antisense construct inhibited entry of the hepatocytes into the S-phase. Regulated induction of the antisense c-myc by dexamethasone for up to 6 h in culture, did not interfere with the entry of hepatocytes into the S-phase. c-myc expression was shown to be required between 6 and 12 h in dHGF-stimulated hepatocytes, and inhibition of its expression during this time by the antisense myc construct did not allow these cells to enter the S-phase. Inhibition of c-myc biosynthesis between 24 and 48 h hours slightly affected the DNA synthetic response. It is proposed that the expression of c-Myc protein interferes with the "priming' of hepatocytes to become responsive to growth-factor stimuli, or in the absence of such stimuli it interferes with the maintenance of a non-proliferating phenotype and subsequent in vitro de-differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670166      PMCID: PMC1217432          DOI: 10.1042/bj3160879

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

Review 1.  Preparation of isolated rat liver cells.

Authors:  P O Seglen
Journal:  Methods Cell Biol       Date:  1976       Impact factor: 1.441

2.  Proto-oncogene expression in regenerating liver is simulated in cultures of primary adult rat hepatocytes.

Authors:  W Kruijer; H Skelly; F Botteri; H van der Putten; J R Barber; I M Verma; H L Leffert
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

3.  Proliferating cell nuclear antigen immunolocalization in gastro-intestinal epithelia.

Authors:  C E Sarraf; C S McCormick; G R Brown; Y E Price; P A Hall; D P Lane; M R Alison
Journal:  Digestion       Date:  1991       Impact factor: 3.216

4.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells.

Authors:  S R Hann; R N Eisenman
Journal:  Mol Cell Biol       Date:  1984-11       Impact factor: 4.272

5.  Regulated transcription of c-Ki-ras and c-myc during compensatory growth of rat liver.

Authors:  M Goyette; C J Petropoulos; P R Shank; N Fausto
Journal:  Mol Cell Biol       Date:  1984-08       Impact factor: 4.272

6.  Microinjected c-myc as a competence factor.

Authors:  L Kaczmarek; J K Hyland; R Watt; M Rosenberg; R Baserga
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

7.  Differential responsiveness of myc- and ras-transfected cells to growth factors: selective stimulation of myc-transfected cells by epidermal growth factor.

Authors:  D F Stern; A B Roberts; N S Roche; M B Sporn; R A Weinberg
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

8.  C-myc transcript is induced in rat liver at a very early stage of regeneration or by cycloheximide treatment.

Authors:  R Makino; K Hayashi; T Sugimura
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

9.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Authors:  G I Evan; G K Lewis; G Ramsay; J M Bishop
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

10.  Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle.

Authors:  P H Rabbitts; J V Watson; A Lamond; A Forster; M A Stinson; G Evan; W Fischer; E Atherton; R Sheppard; T H Rabbitts
Journal:  EMBO J       Date:  1985-08       Impact factor: 11.598

View more
  5 in total

1.  Priming of hepatocytes enhances in vivo liver transduction with lentiviral vectors in adult mice.

Authors:  Virginie Pichard; Sébastien Boni; William Baron; Tuan Huy Nguyen; Nicolas Ferry
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

2.  Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription.

Authors:  Kevin A Walter; Mir Ahamed Hossain; Carey Luddy; Nidhi Goel; Thomas E Reznik; John Laterra
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  Proliferation and invasion: plasticity in tumor cells.

Authors:  Chong-Feng Gao; Qian Xie; Yan-Li Su; Julie Koeman; Sok Kean Khoo; Margaret Gustafson; Beatrice S Knudsen; Rick Hay; Nariyoshi Shinomiya; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-15       Impact factor: 11.205

4.  Statins decrease the expression of c-Myc protein in cancer cell lines.

Authors:  Prema S Rao; U Subrahmanyeswara Rao
Journal:  Mol Cell Biochem       Date:  2020-10-17       Impact factor: 3.396

5.  Aberrant MFN2 transcription facilitates homocysteine-induced VSMCs proliferation via the increased binding of c-Myc to DNMT1 in atherosclerosis.

Authors:  Long Xu; Hongyi Hao; Yinju Hao; Guo Wei; Guizhong Li; Pengjun Ma; Lingbo Xu; Ning Ding; Shengchao Ma; Alex F Chen; Yideng Jiang
Journal:  J Cell Mol Med       Date:  2019-05-18       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.